再颁专利
- 专利标题: Enzyme inhibitors
- 专利标题(中): 酶抑制剂
-
申请号: US10407204申请日: 1995-06-14
-
公开(公告)号: USRE39576E1公开(公告)日: 2007-04-17
- 发明人: Harold Francis Hodson , Richard Michael John Palmer , David Alan Sawyer , Richard Graham Knowles , Karl Witold Franzmann , Martin James Drysdale , Patricia Ifeyinwa Davies , Helen Alice Rebecca Clark , Barry George Shearer , Steven Smith
- 申请人: Harold Francis Hodson , Richard Michael John Palmer , David Alan Sawyer , Richard Graham Knowles , Karl Witold Franzmann , Martin James Drysdale , Patricia Ifeyinwa Davies , Helen Alice Rebecca Clark , Barry George Shearer , Steven Smith
- 申请人地址: US PA Philadelphia
- 专利权人: Smithkline Beecham Corporation
- 当前专利权人: Smithkline Beecham Corporation
- 当前专利权人地址: US PA Philadelphia
- 代理机构: Nixon & Vanderhye P.C.
- 优先权: EP94304314 19940615; GB9509774 19950515
- 国际申请: PCT/GB95/01378 WO 19950614
- 国际公布: WO95/34534 WO 19951221
- 主分类号: A61K31/195
- IPC分类号: A61K31/195
摘要:
A compound of formula (I) wherein R1 is a C1-6 straight or branched chain alkyl group, a C2-6alkenyl group, a C2-6 alkynyl group, a C3-6cycloalkyl group or a C3-6cycloalkylC1-6alkyl group, each optionally substituted by one to three groups independently selected from: —CN; —NO2; a group —COR2 wherein R2 is hydrogen, C1-6 alkyl, —OR3 wherein R3 is hydrogen or C1-6alkyl or NR4R5 wherein R4 and R5 are independently selected from hydrogen or C1-6 alkyl; a group —S(O)mR6 wherein m is 0, 1 or 2, R6 is hydrogen, C1-6 alkyl, hydroxy or NR7R8 wherein R7 and R8 are independently hydrogen or C1-6 alkyl; a group PO(OR9)2 wherein R9 is hydrogen or C1-6 alkyl; a group NR10R11 wherein R10 and R11 are independently selected from hydrogen, C1-6 alkyl, —COR12 wherein R12 is hydrogen or C1-6 alkyl, or —S(O)m′R13 wherein m′ is 0, 1 or 2 and R13 is hydrogen or C1-6 alkyl; halo; or a group —OR14 wherein R14 is hydrogen, C1-6 alkyl optionally substituted by one to three halo atoms, C6-10 aryl or —COR15 wherein R15 is hydrogen or C1-6 alkyl; p is 2 or 3, q is 1 or 2 and n is 0 or 1 and all salts, esters, amides and physiologically acceptable prodrugs thereof; pharmaceutical uses and formulations therefor; and processes for their preparation are disclosed.
信息查询